Table 3. A comparison of the European and American CLSI threshold values for cefotaxime.
Antibacterial substance | Organism-specific threshold value assignments | |||||||||||
Entero-bacteriaceae | Pseudomonas | Acinetobacter | Staphylococcus | Enterococcus | Streptococcus A, B, C, G | Streptococcus pneumoniae | Haemophilus influenzae M. catarrhalis | N. gonorrhoeae | N. meningitidis | Anaerobes | ||
CLSI | Cefotaxim | ≤ 8/≥ 64 | ≤ 8/≥ 64 | ≤ 8/≥ 64 | ≤ 16/≥ 64 | – | ≤ 0.5/– | ≤ 1/>4 | ≤ 2/– | ≤ 0.5/– | – | |
EUCAST | Cefotaxim | ≤ 1/≥ 2 | – | – | * | – | ≤ 0.5/> 0.5 | ≤ 0.5/> 2 | ≤ 0.12/> 0.12 | ≤ 0.12/> 0.12 | ≤ 0.12/> 0.12 | – |
* The test results for staphylococci and methicillin (as well as oxacillin and cefoxitin) are applicable to all intravenously administered cephalosporins with the exception of ceftazidime, which should not be used to treat staphylococcal infections.
CLSI, Clinical Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility.